Treatment of Stage IIa Classical Hodgkin Lymphoma
For an adult with stage IIa classical Hodgkin lymphoma, the recommended treatment is 2 cycles of ABVD chemotherapy followed by 20 Gy involved-site radiotherapy (ISRT) for favorable disease, or 4 cycles of ABVD followed by 30 Gy ISRT for unfavorable disease, based on risk stratification. 1
Risk Stratification is Critical
Stage IIa disease must first be classified as either early favorable or early unfavorable based on specific risk factors. The presence of any of the following defines unfavorable disease 1:
- Elevated erythrocyte sedimentation rate (ESR)
- Large mediastinal mass (>10 cm or >1/3 thoracic diameter at T5-T6)
- Extranodal involvement
- Three or more nodal sites involved
- Age considerations (varies by protocol)
- B symptoms in some classification systems
Treatment Algorithm
For Early Favorable Stage IIa (No Risk Factors):
- 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
- Followed by 20 Gy ISRT
- Expected 5-year overall survival: ~94% 2
For Early Unfavorable Stage IIa (≥1 Risk Factor):
- 4 cycles of ABVD
- Followed by 30 Gy ISRT
- Expected 5-year overall survival: ~97% 2
Alternative PET-adapted approach (based on EORTC/LYSA/FIL H10 study): Start with 2 cycles of ABVD, perform interim PET-CT, then:
- If PET-negative (Deauville score ≤2): 1 additional cycle of ABVD + 20 Gy ISRT
- If PET-positive (Deauville score ≥3): Switch to 2 cycles of escalated BEACOPP + 30 Gy ISRT 1
Important Caveats and Pitfalls
The debate about omitting radiotherapy: While some trials have explored omitting RT in PET-negative patients after chemotherapy, the evidence consistently shows superior progression-free survival with combined-modality therapy 1. Chemotherapy alone may be considered only in highly selected individual patients where late RT toxicity risks clearly outweigh benefits, but this represents a deviation from standard care with accepted increased relapse risk.
ISRT has replaced older, larger radiation fields (involved-field RT or extended-field RT), reducing long-term toxicity while maintaining excellent disease control 1. The shift to smaller radiation volumes is supported by ILROG guidelines and represents current best practice.
Bleomycin toxicity monitoring is essential during ABVD treatment. Pulmonary function should be assessed, and bleomycin discontinued if pulmonary toxicity develops 1.
Why This Approach Prioritizes Outcomes
This combined-modality strategy achieves cure rates exceeding 90% while minimizing both acute toxicity and long-term complications 3, 1. The risk-adapted approach ensures that patients with favorable disease receive less intensive therapy (reducing late effects like secondary malignancies, cardiovascular disease, and infertility), while those with unfavorable features receive appropriately intensified treatment to maintain excellent disease control.
PET-CT should be performed after completion of therapy to assess response and guide follow-up 1. Interim PET after 2 cycles can guide treatment intensification in unfavorable cases but should not routinely be used to omit radiotherapy in favorable cases given the PFS advantage of combined-modality therapy.
The NCCN 3 and ESMO 1 guidelines uniformly support this risk-adapted, combined-modality approach as Category 2A (uniform consensus based on lower-level evidence) and Level I-A evidence respectively, reflecting the strong consensus across international expert panels.